The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY (Part 2 Of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Company gradually has revised its business model, moving into earlier-stage research, largely through the acquisition of two biotechs in the past year.
You may also be interested in...
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
The Medicines Co. Pulls European Application For Oritavancin
Specialty pharma plans to investigate antibiotic as single-dose, 1,200 mg therapy after FDA and EMEA turned down proposed 200 mg, multi-day dosing.